Abbott Plans Spin-Off Of Global Nutrition Business By End Of 2027

Abbott announced plans to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to existing shareholders, with completion expected by the end of 2027. The new company will generate approximately $8.5 billion in annual sales and operate with about 16,000 employees across 14 manufacturing sites, with leading brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure. Abbott Chairman and CEO Robert B. Ford said the separation will allow both companies to pursue distinct growth strategies, while Abbott focuses on its medical devices, diagnostics and established medicines businesses.

FOUNDER: Dr. Wallace Calvin Abbott

HQ: North Chicago, Illinois

#VentureCapitalV #Abbott #DrWallaceCalvinAbbott #TradedVC